Skip to content

Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients

From Feasibility to Efficacy: the Use of EMDR to Reduce Craving and Drinking Behaviour in Alcohol Dependent Outpatients - A Multiple Baseline Study and Randomized Controlled Trial (RCT)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01828866
Enrollment
109
Registered
2013-04-11
Start date
2013-09-30
Completion date
2016-08-31
Last updated
2016-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Dependence

Keywords

EMDR, Alcohol, Relapse, Craving

Brief summary

One interesting approach to the treatment of addiction is the use of Eye Movement Desensitization and Reprocessing (EMDR) (Shapiro, 1989). Although research on the feasibility and efficacy of EMDR on addiction is limited and often lacks methodological rigor, the results are promising and suggest that further research on this subject is warranted. This proposal consists of two studies to test and determine the acceptability, feasibility and efficacy of EMDR as an intervention to reduce craving and alcohol use in alcohol dependent outpatients as well as to gain further understanding in underlying working mechanisms.

Interventions

BEHAVIORALEMDR

EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.

CRA is based on behavioural therapy principles: 1. Functional analysis 2. Communication skills 3. Problem-solving skills 4. Sobriety sampling 5. Social networking 6. Refusal of substances 7. Reinforcing activities 8. Relapse management 9. Medication monitoring

Sponsors

Fonds Psychische Gezondheid
CollaboratorOTHER
Dutch EMDR Association
CollaboratorUNKNOWN
EMDR Research Foundation
CollaboratorUNKNOWN
IrisZorg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* A primary diagnosis of alcohol dependence or abuse (meeting the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-TR criteria (American Psychiatric Association, 2000); * Age of at least 18 years or older; * Can speak and read Dutch language; * Consent (written) to postponed information given.

Exclusion criteria

* Meeting the DSM-IV-TR (American Psychiatric Association, 2000) criteria for current (in the past 2 weeks) addiction and regular use (at least once per week in the last two weeks before baseline screening) of drugs other than alcohol or nicotine (relative exclusion: decision on case-by-case basis whether it leads to therapy-interference); * Meeting the DSM-IV (American Psychiatric Association, 2000) criteria for current (in the last two weeks before baseline screening) regular alcohol use (at least \> 21E (women) or \> 28E (men) per week) (relative exclusion: decision on case-by-case basis) (relative exclusion: decision on case-by-case basis whether it leads to therapy-interference); * Meeting the DSM-IV (American Psychiatric Association, 2000) criteria for current post-traumatic stress disorder (PTSD); * Severe, current (since the start of regular treatment) psychiatric symptoms (especially manic, psychotic, suicidal and aggressive symptoms) that may endanger participants or others and jeopardize study adherence.

Design outcomes

Primary

MeasureTime frameDescription
Changes in number of heavy drinking days in the previous 30 daysChanges in baseline number of heavy drinking days in the previous 30 days, at post-intervention, and 1 and 6 month follow-upChanges in patient-reported number of heavy drinking days (defined as days on which 5 or more standard drinks of alcohol were consumed during the previous 30 days, as assessed with the alcohol TimeLine FollowBack (TLFB) method).

Secondary

MeasureTime frameDescription
Drop outUp to 6 months post-interventionDrop-out of study
Changes in alcohol implicit associationsChanges in baseline alcohol implicit associations, at post-intervention, and 1 and 6 month follow-upChanges in alcohol implicit associations as measured by the valence Implicit Association Task (IAT)
Changes in patient-reported cravingChanges in baseline patient-reported craving, at post-intervention, and 1 and 6 month follow-upChanges in patient-reported craving as measured by the Penn Alcohol Craving Scale (PACS)
Changes in patient-reported desire thinkingChanges in baseline patient-reported desire thinking, at post-intervention, and 1 and 6 month follow-upChanges in patient-reported desire thinking as measured by the Desire Thinking Questionnaire (DTQ)
Changes in patient-reported coping self-efficacyChanges in baseline patient-reported coping self-efficacy, at post-intervention, and 1 and 6 month follow-upChanges in patient-reported coping self-efficacy as measured by the Self-Efficacy List for Drug users (SELD)
Changes in patient-reported quality of lifeChanges in baseline patint-reported quality of life, at post-intervention, and 1 and 6 month follow-upChanges in patient-reported quality of life as measured by the EuroQol-5D (EQ-5D) and the Community Reinforcement Approach Happiness scale (CRA-HS)
Changes in patient-reported ruminationChanges in baseline patient-reported rumination, at post-intervention, and 1 and 6 month follow-upChanges in patient-reported rumination as measured by the Perseverative Thinking Questionnaire (PTQ)
Changes in patient-reported positive and negative affectChanges in baseline patient-reported positive and negative affect, at post-intervention, and 1 and 6 month follow-upChanges in patient-reported positive and negative affect as measured by the (translated) International Positive And Negative Affect Scale short-form version (I-PANAS-SF)
Time to first alcohol consumptionUp to 6 months post-interventionTime to first alcohol consumption as measured by the alcohol Timeline FollowBack method (TLFB)
Changes in number of total drinks consumed in the previous 30 daysChanges in baseline number of total drinks consumed in the previous 30 days, at post-intervention, and 1 and 6 month follow-upChanges in number of drinks consumed in the previous 30 days as measured by the alcohol TLFB
Changes in average drinks per occasion in the previous 30 daysChanges in baseline average drinks per occasion in the previous 30 days, at post-intervention, and 1 and 6 month follow-upChanges in average drinks per occasion in the past 30 days as measured by the alcohol TLFB
Changes in severity of patient-reported problematic alcohol useChanges in baseline severity of patient-reported problematic alcohol use, at post-intervention, and 1 and 6 month follow-upChanges in severity of patient-reported problematic alcohol use during the previous month as measured by the Alcohol Use Disorders Identification Test (AUDIT)
Changes in biomarker levelsChange from baseline assessment, at post-intervention, and follow-up after 1 and 6 monthsChanges in biomarker levels as measured by laboratory tests of serum γ-glutamyltransferase (GGT) and carbohydrate-deficient transferrin (CDT)
Changes in alcohol attentional biasChanges in baseline alcohol attentional bias, at post-intervention, and 1 and 6 month follow-upChanges in alcohol attentional bias as measured by the Alcohol Stroop

Other

MeasureTime frameDescription
Patient-reported motivation to stay abstinentBaselinePatient-reported motivation to stay abstinent as measured by the Readiness to Change Questionnaire, Dutch version (RCQ-D)
Psychiatric comorbidityBaselinePsychiatric comorbidity as measured by the Mini-International Neuropsychiatric Interview (MINI-plus)
Use of anti-craving, abstinence enforcing or other psychoactive medicationAt baseline, post-intervention and 1 and 6 month follow-upUse of anti-craving, abstinence enforcing or other psychoactive medication as derived from patient and patient dossier during assessments
Time-in-treatment: total time of TAU (at last assessment)Up to 6 months follow upTime-in-treatment defined by total time of TAU from start of regular treatment until 6 month follow up.
Intensity of treatment: number of treatment sessionsUp until 6 months follow upIntensity of treatment: number of treatment sessions received from start of regular treatment until 6 months follow up
Contents of treatment receivedUp until 6 month follow upTreatment modules received that constitute TAU for a specific participant
History of drinking and other substance useBaselineHistory of drinking and other substance use as measured by the Measurements in the Addictions for Triage and Evaluation (MATE)

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026